Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Stop The Bleeding: Sanofi-Aventis Looks To Sell A Generic Plavix In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

If a bioequivalent version of the clot buster launches in France, Sanofi is preparing to roll out its own generic version of clopidogrel.

You may also be interested in...



AstraZeneca's Brilique Approved In The EU

AstraZeneca's antiplatelet agent Brilique/Brilinta receives its first approval, but pricing negotiations will delay launch in most countries.

AstraZeneca's Brilique Approved In The EU

AstraZeneca's antiplatelet agent Brilique/Brilinta receives its first approval, but pricing negotiations will delay launch in most countries.

Health Reform Magnifies Payers' Invisible Place At The Licensing Table

Report from Licensing Executives Society meeting: Survey shows many already have taken action oncomparative effectiveness.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS068702

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel